Transition Therapeutics to Present at UBS 2007 Global Life Sciences Conference

    TORONTO, Sept. 20 /CNW/ - Transition Therapeutics Inc. ("Transition" or
the "Company") (TSX: TTH, NASDAQ:  TTHI) today announced that Dr. Tony Cruz,
Chairman and Chief Executive Officer, will present at the upcoming UBS 2007
Global Life Sciences Conference. Dr. Cruz's presentation will take place on
Monday September 24, 2007 at 8:00am (Eastern Time) at the Grand Hyatt Hotel in
New York City.
    To access the live audio webcast of the presentation, log on through a
link located on Transition's website at The
webcast will be available for replay following the presentation.

    About Transition

    Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. Transition's lead products include
ELND-005/AZD-103 for the treatment of Alzheimer's disease and regenerative
therapies E1-I.N.T.(TM) and GLP1-I.N.T.(TM) for the treatment of diabetes.
Transition has an emerging pipeline of preclinical drug candidates developed
using its proprietary drug discovery engine. Transition's shares are listed on
the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the
symbol "TTH". For additional information about the company, please visit

    Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be superseded
by more recent information we have disclosed in later press releases, filings
with the OSC, SEC or otherwise. Except for historical information, this press
release may contain forward-looking statements, relating to expectations,
plans or prospects for Transition, including conducting clinical trials. These
statements are based upon the current expectations and beliefs of Transition's
management and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include factors
beyond Transition's control and the risk factors and other cautionary
statements discussed in Transition's quarterly and annual filings with the
Canadian commissions.

    %SEDAR: 00015806E

For further information:

For further information: visit or
contact: Dr. Tony Cruz, Chief Executive Officer, Transition Therapeutics Inc.,
Phone: (416) 260-7770, x.223,; Elie Farah,
Chief Financial Officer, Transition Therapeutics Inc., Phone: (416) 260-7770,

Organization Profile

Transition Therapeutics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890